Subir material

Suba sus trabajos a SEDICI, para mejorar notoriamente su visibilidad e impacto

 

Mostrar el registro sencillo del ítem

dc.date.accessioned 2013-09-16T14:06:01Z
dc.date.available 2013-09-16T14:06:01Z
dc.date.issued 2010
dc.identifier.uri http://sedici.unlp.edu.ar/handle/10915/29442
dc.description.abstract Argentine hemorrhagic fever (AHF) is an endemo-epidemic disease caused by Junín virus (JUNV), a member of the arenaviridae family. Although a recently introduced live attenuated vaccine has proven to be effective, AHF remains a potentially lethal infection. Like in other viral hemorrhagic fevers (VHF), AHF patients present with fever and hemorrhagic complications. Although the causes of the bleeding are poorly understood, impaired hemostasis, endothelial cell dysfunction and low platelet counts have been described. Thrombocytopenia is a common feature in VHF syndromes, and it is a major sign for its diagnosis. However, the underlying pathogenic mechanism has not yet been elucidated. We hypothesized that thrombocytopenia results from a viral-triggered alteration of the megakaryo/thrombopoiesis process. Therefore, we evaluated the impact of JUNV on megakaryopoiesis using an in vitro model of human CD34+ cells stimulated with thrombopoietin. Our results showed that CD34+ cells are infected with JUNV in a restricted fashion. Infection was transferrin receptor 1 (TfR1)-dependent and the surface expression of TfR1 was higher in infected cultures, suggesting a novel arenaviral dissemination strategy in hematopoietic progenitor cells. Although proliferation, survival, and commitment in JUNV-infected cultures were normal, viral infection impaired thrombopoiesis by decreasing in vitro proplatelet formation, platelet release, and P-selectin externalization via a bystander effect. The decrease in platelet release was also TfR1-dependent, mimicked by poly(I:C), and type I interferon (IFN α/ß) was implicated as a key paracrine mediator. Among the relevant molecules studied, only the transcription factor NF-E2 showed a moderate decrease in expression in megakaryocytes from either infected cultures or after type I IFN treatment. Moreover, type I IFN-treated megakaryocytes presented ultrastructural abnormalities resembling the reported thrombocytopenic NF-E2-/- mouse phenotype. Our study introduces a potential mechanism for thrombocytopenia in VHF and other diseases associated with increased bone marrow type I IFN levels. en
dc.language en es
dc.subject Fiebre Hemorrágica Americana es
dc.subject Arenaviridae es
dc.subject Trombocitopenia es
dc.title Junín virus infection of human hematopoietic progenitors impairs in vitro proplatelet formation and platelet release via a bystander effect involving type I IFN signaling en
dc.type Articulo es
sedici.identifier.uri http://www.plospathogens.org/article/info%3Adoi%2F10.1371%2Fjournal.ppat.1000847 es
sedici.identifier.other eid:2-s2.0-77954052983
sedici.identifier.issn 1553-7366 es
sedici.creator.person Pozner, Roberto G. es
sedici.creator.person Ure, Agustín Enrique es
sedici.creator.person Jaquenod De Giusti, Carolina es
sedici.creator.person D'Atri, Lina P. es
sedici.creator.person Italiano, Joseph E. es
sedici.creator.person Torres, Oscar es
sedici.creator.person Romanowski, Víctor es
sedici.creator.person Schattner, Mirta es
sedici.creator.person Gómez, Ricardo Martín es
sedici.subject.materias Bioquímica es
sedici.description.fulltext true es
mods.originInfo.place Facultad de Ciencias Exactas es
sedici.subtype Articulo es
sedici.rights.license Creative Commons Attribution 2.5 Argentina (CC BY 2.5)
sedici.rights.uri http://creativecommons.org/licenses/by/2.5/ar/
sedici.description.peerReview peer-review es
sedici.relation.journalTitle PLoS Pathogens es
sedici.relation.journalVolumeAndIssue vol. 6, no. 4 es


Descargar archivos

Este ítem aparece en la(s) siguiente(s) colección(ones)

Creative Commons Attribution 2.5 Argentina (CC BY 2.5) Excepto donde se diga explícitamente, este item se publica bajo la siguiente licencia Creative Commons Attribution 2.5 Argentina (CC BY 2.5)